InspireMD’s CGuard EPS Featured at the SBHCI Congress in Brazil
June 20 2018 - 7:20AM
InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention
systems (EPS) / thrombus management technologies and neurovascular
devices, today announced that CGuard™ EPS was featured at the SBHCI
Congress, sponsored by the Brazilian Society of Hemodynamics and
Interventional Cardiology, which took place in Curitiba, Brazil
from June 13-15, 2018. The Congress hosted approximately
1,200 participants including doctors from across Brazil and Central
and South America.
As part of the scientific sessions, Dr. Antonio
Micari, MD, PhD of Maria Cecilia Hospital, in Cotignola, Italy,
presented “How to Minimize Complications, the Safe Carotid Artery
Stenting (CAS), Step by Step.” Dr. Micari discussed the
importance of selecting the right type of stent to minimize the
risks of complications in CAS procedures. He presented
CGuard™ EPS as the carotid embolic protection stent system of
choice. In addition to his presentation he also showed a
challenging and successful case that utilized the CGuard™ EPS which
employs the company’s patented MicroNet™ PET fiber and SmartFit™
Technology.
“We are pleased to have had CGuard™ EPS featured
so prominently at the SBHCI Congress in Brazil, which included over
a thousand attendees from across Central and South America,”
commented James Barry, PhD, Chief Executive Officer of InspireMD.
“We particularly appreciate the continued support from Dr. Micari
from Maria Cecilia hospital, one of the leading endovascular
surgery facilities in Italy and one of the leaders in the world
doing more than 40,000 endovascular procedures per year.
Regional congresses such as SBHCI are central to our strategy as we
expand our footprint and generate awareness among both key opinion
leaders and leading physicians in Latin America.”
About InspireMD, Inc.
InspireMD seeks to utilize its patented MicroNet™
technology to make its products the industry standard for embolic
protection and to provide a superior solution to the key clinical
issues of current stenting in patients with a high risk of distal
embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this
MicroNet technology in coronary, carotid (CGuard™), neurovascular,
and peripheral artery procedures. InspireMD's common stock is
quoted on the NYSE American under the ticker symbol NSPR and
certain warrants are quoted on the NYSE American under the ticker
symbol NSPR.WS and NSPR.WSB.
Forward-looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words
"intends," "may," "will," "plans," "expects," "anticipates,"
"projects," "predicts," "estimates," "aims," "believes," "hopes,"
"potential" or similar words. Forward-looking statements are not
guarantees of future performance, are based on certain assumptions
and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company's control, and
cannot be predicted or quantified and consequently, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include,
without limitation, risks and uncertainties associated with (i)
market acceptance of our existing and new products, (ii) negative
clinical trial results or lengthy product delays in key markets,
(iii) an inability to secure regulatory approvals for the sale of
our products, (iv) intense competition in the medical device
industry from much larger, multinational companies, (v) product
liability claims, (vi) product malfunctions, (vii) our limited
manufacturing capabilities and reliance on subcontractors for
assistance, (viii) insufficient or inadequate reimbursement by
governmental and other third party payers for our products, (ix)
our efforts to successfully obtain and maintain intellectual
property protection covering our products, which may not be
successful, (x) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (xi) our
reliance on single suppliers for certain product components, (xii)
the fact that we will need to raise additional capital to meet our
business requirements in the future and that such capital raising
may be costly, dilutive or difficult to obtain and (xiii) the fact
that we conduct business in multiple foreign jurisdictions,
exposing us to foreign currency exchange rate fluctuations,
logistical and communications challenges, burdens and costs of
compliance with foreign laws and political and economic instability
in each jurisdiction. More detailed information about the Company
and the risk factors that may affect the realization of forward
looking statements is set forth in the Company's filings with the
Securities and Exchange Commission (SEC), including the Company's
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC's web site at http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events or otherwise.
Investor Contacts:
InspireMD, Inc.
Craig Shore
Chief Financial Officer
Phone: 1-888-776-6804 FREE
Email: craigs@inspiremd.com
Crescendo Communications, LLC
David Waldman
Phone: (212) 671-1021
Email: NSPR@crescendo-ir.com